tbuckley/cabot-search huggingface dataset:
Summary of the Proceedings of the Joint U.S.—U.S.S.R. Symposium on Mammalian Somatic Cell Genetics Related to Neoplasia2
Authors: Joseph A. DiPaolo, Rosemary Cuddy
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Summary of the Proceedings of the Joint U.S.—U.S.S.R. Symposium on Mammalian Somatic Cell Genetics Related to Neoplasia Get access Joseph A. DiPaolo, Joseph A. DiPaolo Search for other works by this author on: Oxford Academic PubMed Google Scholar Rosemary Cuddy Rosemary Cuddy Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 6, December 1975, Pages 1369–1371, https://doi.org/10.1093/jnci/55.6.1369 Published: 01 December 1975 Article history Received: 21 March 1975 Accepted: 22 July 1975 Published: 01 December 1975
Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study
Journal: New England Journal of Medicine (1990)

Atrial fibrillation, even in the absence of rheumatic valvular disease, predisposes patients to embolic complications, but the role of antithrombotic therapy in the prevention of such complications has not been fully clarified. We therefore performed a randomized, placebo-controlled trial to evaluate warfarin and aspirin individually as prophylaxis against ischemic stroke and systemic embolism (the primary events) in such patients.
Preferences in social media in patients with obstructive lung disease
Authors: Jose M. Vilema, Juan C. Calderon, Annia J. Cherrez Chica, German D. Ramon, Blanca M. Morfin-Maciel, Alan P. Baptist, Orlando Lopez-Jove, Erick Calero, Jose Cano, Karin Plaza, Ivan Cherrez Ojeda
Journal: Journal of Allergy and Clinical Immunology (2017)
Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.
Authors: Brian Van Ness, John Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Emily Blood, Antje Hoering, Bart Barlogie, Philip Greipp, Brian Durie
Journal: Blood (2005)
TMOD-20. ESTABLISHMENT OF A BRAIN TUMOR MODEL WITH DYSFUNCTIONAL TUMOR IMMUNITY IN MICE AS A PLATFORM FOR IMMUNOTHERAPEUTIC EVALUATION
Authors: Hiroshi Nakashima, Quazim Alayo, Pablo Penaloza, Dan Barouch, E. Antonio Chiocca
Journal: Neuro-Oncology (2016)

Several clinical trials are currently underway for patients with newly diagnosed and recurrent glioblastoma to reinvigorate tumor immunity using immune-checkpoint blockade. However, the CNS is immunologically unique in its maintenance of an immunosuppressive environment, to protect brain cells from autoimmunity and inflammation. Thus, immunotherapy of brain tumors requires novel regimens to overcome tumor immuno-suppression. Suitable preclinical animal models with exhausted tumor-specific immunity are currently not available. We thus hypothesized that a chronic LCMV (cLCMV) strain that induces T cell exhaustion in mice may be co-opted to model the impaired immunity that characterizes brain tumors. In this model, naïve and cLCMV-infected mice failed to reject a challenge with glioma in brain when murine glioma cells express one of LCMV antigens (VA-glioma) that are presented via MHC-I. In contrast, mice preimmunized with the acutely-controlled LCMV (aLCMV) strain did reject VA-glioma. In fact, in vitro co-culture of lymphocytes and glioma cells, and in vivo TIL analyses suggested that VA-glioma failed to induce CD8+ T cell responses in cLCMV-mice, in contrast to the robust CD8+ T cell response in aLCMV-mice. Furthermore, cLCMV-specific CD8 T cells lacked a central memory T cell phenotype (CD44+, CD62L-, CD127-) and expressed significantly high levels of PD-1. Treatment with anti-PD1, but not isotype control antibody, successfully reinvigorated and restored antitumor immunity in cLCMV-mice that received VA-glioma cells. PD-1 blockade led to significantly improved survival. However, this treatment did not show a therapeutic effect in cLCMV-mice that received parental glioma cells that don’t express the viral antigen. These data strongly suggest that PD-1 blockade is effective in brain tumors that induce impaired tumor-specific T cell immunity. In conclusion, this novel mouse model may be useful to screen for novel immune checkpoint inhibitors and combination regimes in the setting of a single dysfunctional CD8 T cell response.
Perinatal Negative Life Event in Mother Increases the Risk of Allergic Rhinitis in Female Offspring: The PSKC study
Authors: Jisun Yoon, Eun Mi Kim, Mi Young Lee, Hyun-Ju Cho, Yeongho Kim, Eun Lee, Song-I. Yang, Young-Ho Jung, Ju-Hee Seo, So-Yeon Lee, Jung Lym Lee, Ye Jin Lee, Soo-Jong Hong
Journal: Journal of Allergy and Clinical Immunology (2017)
Major surgeries in patients with metastatic colorectal cancer in the United States.
Authors: S. Wang, S. K. Gao, B. Barber, V. J. Wagner, Z. Zhao
Journal: Journal of Clinical Oncology (2011)

e19633 Background: The objective of this study was to examine the proportion of major surgeries in patients with colorectal cancer after diagnosis of metastatic disease (mCRC). Methods: Using a large U.S. medical claims database from a nationally commercially-insured population, patients with diagnosed mCRC between January 2004 and March 2010 were identified. The first metastasis diagnosis date served as the index date. Patients were followed from the index date until end of data collection, death, or end of the study period (March 31, 2010), whichever occurred first. Major surgery was defined according to the list of major surgeries developed by the National Committee for Quality Assurance (NCQA) using Current Procedural Terminology (CPT) procedure codes. Major surgeries were examined by anatomic locations: 1) colon or rectum; 2) liver or lung; and 3) all other anatomic sites. Major surgeries on colon or rectum were assessed separately, since they likely include a high percentage of interventions to remove primary tumors. The proportion of major surgeries was descriptively analyzed. Results: A total of 4,768 mCRC patients who met the study inclusion and exclusion criteria between January 2004 and March 2010 were included in the analyses. Average age was 60.0 years and 45.9% of patients were female. Average length of follow-up observation time was over one year (414 days). Overall, 42.3% of patients had at least one major surgery on anatomic sites other than colon/rectum after mCRC diagnosis. By anatomic locations, 17.6% of patients had major surgeries on liver or lung (13.4% on liver and 4.9% on lung); and 32.3% had major surgeries on all other anatomic sites. Major surgeries on colon or rectum occurred in 35.9% of patients (32.9% on colon and 4.1% on rectum). Conclusions: Major surgeries are highly prevalent in patients with mCRC from this commercially insured population after mCRC diagnosis. This might have implications for anticancer drug therapy in mCRC patients.
Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation
Authors: Kerry J. Savage, Joseph M. Connors, Diego R Villa, Greg Hapgood, Alina S Gerrie, Tamara N Shenkier, David W Scott, Randy D. Gascoyne, Francois Benard, James Morris, Tom Pickles, Christina Parsons, Don Wilson, Laurie H. Sehn
Journal: Blood (2015)
Incidental renal tumors in cancer survivors: Minimally invasive management by image-guided thermal ablation.
Authors: Mohamed E. Abdelsalam, Sharjeel H Sabir, Samuel B. Kusin, Surena F. Matin, Christopher G. Wood, Jose A. Karam, Kamran Ahrar
Journal: Journal of Clinical Oncology (2016)

258 Background: To investigate presentation, management and outcome of renal tumors in patients with prior or current history of cancer. Methods: A retrospective review of a database for patients undergoing ablation of renal tumors between January 2012 and June 2014 was performed. For each patient , the following was recorded: Prior or current history of cancer (other than renal cell carcinoma), histology of primary tumor, status of primary cancer (remission or under therapy), size of the renal tumor, thermal ablation technology , complications of ablation, development of metastases from renal tumor, deceased or alive , cause of death and the length of follow up. Results: Ninety five renal ablation procedures were performed in 91 patients between January 2012 and June 2014. Of this subset, 37 patients (27 male and 10 females) with average age 63 years (Age range 53-85 Years) had prior or current history of malignancy (6 patients had more than one primary cancer) other than renal tumor including Prostate(6), colorectal (4), Breast (4) lymphoma (3) and others (20). All renal tumors were discovered incidentally, none of the patients had symptoms related to renal tumors. Twenty four patients were in remission and 13 patients were undergoing therapy for their primary malignancy at the time of ablation. Ablation was performed using radiofrequency (n = 30) or cryoablation (n = 9) for 39 renal lesions with average size of 2.4cm (Range 1.1 to 4 cm). After average of 20 months (range 5-35 months) of observation 34 patients (92%) were still alive. Three patients died of their primary cancer. None of the patients developed complication from the procedure, 1 patient had recurrence after 6 month; for which renal ablation was performed. None of the patients developed metastatic disease from or died of renal cell carcinoma. Conclusions: Staging workup and surveillance imaging studies in cancer patients can lead to incidental detection of primary renal tumors. Minimally invasive therapy with image guided radiofrequency ablation or cryotherapy is feasible, safe and effective. Image guided ablation has no discernable impact on the course of therapy for the primary tumor. Furthermore, it has minimal to no morbidity for patients in remission.
152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours
Authors: V. Teneggi, M. Ng, D.S. Tan, V. Subbiah, C. Weekes, V. Diermayr, K. Ethirajulu, P. Yeo, D. Chen, S. Gan, S. Blanchard, R. Nellore, M.A. Lee, J. Hill, D. Virshup, B. Madan, A. Matter
Journal: Annals of Oncology (2016)
Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.
Authors: Maureen O'Brien, Gary Dahl, Stanley Pounds, Norman J. Lacayo, Jeffrey Taub, Myron Chang, Howard J. Weinstein, Yaddanapudi Ravindranath, Dario Campana, Ching-Hon Pui, Jeffrey Rubnitz
Journal: Blood (2009)
p38 alpha MAP Kinase Inhibitor Inhibits Human Myeloma Cell Growth in Vivo.
Authors: Mamatha Reddy, Jing Y. Ma, Irene Kerr, Nirupama Henjarappa, Tony Navas, Jit Chakravarty, Sundeep Dugar, Linda S. Higgins, Andrew A. Protter, Satyanarayana Medicherla
Journal: Blood (2004)
Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea
Authors: Cecilia Turino, Jordi de Batlle, Holger Woehrle, Ana Mayoral, Anabel Lourdes Castro-Grattoni, Sílvia Gómez, Mireia Dalmases, Manuel Sánchez-de-la-Torre, Ferran Barbé
Journal: European Respiratory Journal (2017)

Continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnoea (OSA), but treatment compliance is often unsatisfactory. This study investigated the efficacy and cost-effectiveness of telemonitoring for improving CPAP compliance. 100 newly diagnosed OSA patients requiring CPAP (apnoea–hypopnoea index &gt;15 events·h −1 ) were randomised to standard management or a telemonitoring programme that collected daily information about compliance, air leaks and residual respiratory events, and initiated patient contact to resolve issues. Clinical/anthropometric variables, daytime sleepiness and quality of life were recorded at baseline and after 3 months. Patient satisfaction, additional visits/calls, side-effects and total costs were assessed. There were no significant differences between the standard and telemedicine groups in terms of CPAP compliance (4.9±2.2 versus 5.1±2.1 h·night −1 ), symptoms, clinical variables, quality of life and unwanted effects. Telemedicine was less expensive than standard management (EUR123.65 versus EUR170.97; p=0.022) and was cost-effective (incremental cost-effectiveness ratio EUR17 358.65 per quality-adjusted life-year gained). Overall patient satisfaction was high, but significantly more patients rated satisfaction as high/very high in the standard management versus telemedicine group (96% versus 74%; p=0.034). Telemonitoring did not improve CPAP treatment compliance and was associated with lower patient satisfaction. However, it was more cost-effective than traditional follow-up.
Prospective randomized trial of natural interferon-alpha (IFN) versus IFN + cimetidine in advanced renal cell carcinoma with pulmonary metastasis
Authors: T. Kinouchi, J. Sakamoto, T. Tsukamoto, H. Akaza, Y. Kubota, S. Ozono, H. Kanetake, T. Taguchi, T. Kotake
Journal: Journal of Clinical Oncology (2004)

4676 Background: In the preliminary non-randomized study, combination therapy with natural IFN plus cimetidine showed high response rate in 15 out of 37 patients (41%) for advanced renal cell carcinoma. A prospective randomized multiinstitutional clinical trial to compare the effect of IFN alone to IFN + cimetidine in patients with advanced renal cell carcinoma with pulmonary metastasis was performed. Methods: Patients received IFN (5 megaunits) 5 times a week, or the IFN regimen plus daily oral cimetidine (800 mg). The primary end point was response rate, and time to progression (TTP). The secondary end point was overall survival. Results: Between April 1998 and March 2002, 71 patients from 32 institutions were randomly assigned to the two treatment groups. One patient in each group was found to be ineligible because they did not receive IFN at all. Two patients in IFN alone group stopped the treatment on day 9 and on day 10. Among 36 patients in IFN alone group, one CR, 4 PRs, 16 NCs, and 12 PDs were shown, with a response rate of 15.2%. Of 35 patients in IFN + cimetidine group, two CRs, 8 PRs, 13 NCs, and 11 PDs were observed, with a response rate of 29.4%. The difference was not significant (P=0.34). TTP ranged from 9 to 2307 days (median 179 days) in the IFN alone group, and from 31 to 3030 days (median 178 days) in IFN plus cimetidine group (p=0.86). The overall survival between the two groups was not significantly different either. The responses in pulmonary site were 1 CR, 3 PRs, 20 NCs, and 9 PDs in the IFN alone group, and 2 CRs, 7 PRs, 17 NCs, and 7 PDs in the combination therapy group (P=0.13). Conclusions: The combined treatment with IFN + cimetidine for advanced renal cell carcinoma could not have shown significant improvement in response rates or survival compared to IFN alone therapy. No significant financial relationships to disclose.
After the Fall — Prophylaxis for All?
Authors: Stephan Moll
Journal: New England Journal of Medicine (2017)

Nearly 1 million patients undergo knee arthroscopy in the United States every year.1 The incidence of symptomatic venous thromboembolism in this patient population is approximately 0.6%, or nearly 4000 patients per year.1,2 Published evidence for the benefit of prophylactic anticoagulation in patients undergoing knee arthroscopy has been of low or moderate quality, and on the basis of this evidence, the 2012 American College of Chest Physicians (ACCP) guidelines do not recommend the use of thromboprophylaxis in patients who do not have a history of venous thromboembolism.3 The National Institute for Health and Care Excellence (NICE) recommendations for hospitalized patients . . .
Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
Authors: A. Le Cesne, J.-Y. Blay, D. Cupissol, A. Italiano, C. Delcambre, N. Penel, N. Isambert, C. Chevreau, E. Bompas, F. Bertucci, L. Chaigneau, S. Piperno-Neumann, S. Salas, M. Rios, C. Guillemet, J.-O. Bay, I.L. Ray-Coquard, O. Mir, L. Haddag, S. Foulon
Journal: Annals of Oncology (2016)
Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)
Authors: Sergio Cortelazzo, Corrado Tarella, Alessandro Massimo Gianni, Tiziano Barbui, Marco Ladetto, Anna Maria Barbui, Andrea Rossi, Paolo Corradini, Massimo Di Nicola, Caterina Patti, Antonino Mulé, Manuela Zanni, Valerio Zoli, Atto Billio, Andrea Gallamini, Francesco Di Raimondo, Andrés J.M. Ferreri, Giovanni Pizzolo, Giorgio La Nasa, Pietro Leoni, Giampietro Semenzato, Maurizio Frezzato, Leonardo Flenghi, Marco Scarano, Arianna Masciulli, Roberto Marchioli, Alessandro Rambaldi
Journal: Blood (2012)
Law change will foster doctors’ honest discussion of mistakes, says Hunt
Authors: Abi Rimmer
Journal: BMJ (2017)

Doctors will be able to have honest discussions about mistakes after the introduction of new legislation to ensure that information used in investigations is kept confidential, England’s health secretary has said.

Speaking at a Westminster Health Conference in London on Thursday 26 January, Jeremy Hunt said that the government planned to change the way that investigations into incidents in the NHS were dealt with. He said that when mistakes were made doctors were often left unable to “sit down openly and honestly and talk about what happened and learn from this and spread …
Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy
Authors: Daniel A. Orringer, Balaji Pandian, Yashar S. Niknafs, Todd C. Hollon, Julianne Boyle, Spencer Lewis, Mia Garrard, Shawn L. Hervey-Jumper, Hugh J. L. Garton, Cormac O. Maher, Jason A. Heth, Oren Sagher, D. Andrew Wilkinson, Matija Snuderl, Sriram Venneti, Shakti H. Ramkissoon, Kathryn A. McFadden, Amanda Fisher-Hubbard, Andrew P. Lieberman, Timothy D. Johnson, X. Sunney Xie, Jay K. Trautman, Christian W. Freudiger, Sandra Camelo-Piragua
Journal: Nature Biomedical Engineering (2017)
The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,
Authors: Meletios A Dimopoulos, Maria Roussou, Maria Gkotzamanidou, Erasmia Psimenou, Despoina Mparmparoussi, Charis Matsouka, Evangelos Terpos, Efstathios Kastritis
Journal: Blood (2011)
Third-line salvage chemotherapy for recurrent cervical cancer.
Authors: D. B. Manders, S. C. Purinton, J. Lea, D. S. Miller, S. M. Kehoe, D. L. Richardson
Journal: Journal of Clinical Oncology (2011)

e15510 Background: Recurrent cervical cancer with extrapelvic disease is incurable. Patients with recurrent disease may undergo multiple salvage chemotherapy regimens to prolong life or alleviate symptoms. There is limited data regarding efficacy and toxicity of chemotherapy in heavily pretreated cervical cancer patients. We describe the response rate, toxicity, progression-free survival (PFS) and overall survival (OS) in patients receiving 3rd line chemotherapy for recurrent cervical cancer. Methods: A chart review of patients at a single institution who, between 1/1/1995 and 1/1/2010, were diagnosed with recurrent or persistent cervical cancer and who received at least three different salvage regimens was performed. Response rates were measured using RECIST criteria. Toxicities were graded using the CTCAEv4.0. PFS and OS were calculated using Kaplan Meier curves. Results: 17 of 758 patients in the cervical cancer database met inclusion criteria. The median age was 43 (range 29-84). Third-line salvage regimens included vinorelbine (7 patients), paclitaxel (6) and others (4). The median number of cycles was 4 (range 1-11). One patient had a complete response and one had a partial response for a response rate of 12%. Common toxicities were anemia (82%, including 24% grade 3/4) and infection (35%, including 18% grade 3/4). Median PFS was 3.2 months (1.4-7 months), and median OS was 7.4 months (1.7-34.7 months). Median follow up from time of third-line treatment was 7 months (range 2-34). 6 patients (35%) went on to receive fourth-line chemotherapy. 16 patients (94%) are dead of disease. Conclusions: Third-line chemotherapy for recurrent cervical cancer has minimal activity and is associated with significant toxicity. Patients who have failed two salvage regimens are unlikely to derive further benefit from currently available agents. Consideration should be given to enrolling these patients in clinical trials or offering best supportive care.
Annals Story Slam - The First Delivery
Authors: Abigail Wolf
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - The First DeliveryFREEAbigail Wolf, MDAbigail Wolf, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0017 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The First Delivery "The First Delivery," by Abigail Wolf, MD (Duration 5:26)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Abigail Wolf, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Abigail.[email protected]edu PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Higher Titer of Epstein-Barr Virus Nuclear Antigen Might be a Marker of Poorer Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Authors: Yoshiharu Kusano, Yasuhito Terui, Kyoko Ueda, Masahiro Yokoyama, Noriko Nishimura, Yuko Mishima, Tadahiro Gunji, Hideaki Nitta, Anna Takahasi, Norihito Inoue, Kiyohiko Hatake
Journal: Blood (2015)